The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

Abstract Background Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of non-small cell lung cancer harboring EGFR mutations. However, 40 mg dai...

Full description

Bibliographic Details
Main Authors: Chih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, Mei-Hsuan Lee, Ying-Ming Tsai, Yu-Chen Tsai, Jui-Feng Hsu, Ta-Chih Liu, Ming-Shyan Huang, Inn-Wen Chong
Format: Article
Language:English
Published: BMC 2017-12-01
Series:BMC Pharmacology and Toxicology
Subjects:
Lung cancer
Adenocarcinoma
Afatinib
Epidermal growth factor receptor
Tyrosine kinase inhibitor;diarrhea
Adverse drug reaction
Online Access:http://link.springer.com/article/10.1186/s40360-017-0190-1

Internet

http://link.springer.com/article/10.1186/s40360-017-0190-1

Similar Items